Androgen receptor modulation optimized for response (ARMOR) phase I and II studies: galeterone for the treatment of castration-resistant prostate cancer

B Montgomery, MA Eisenberger, MB Rettig, F Chu… - Clinical Cancer …, 2016 - AACR
Purpose: Galeterone is a selective, multitargeted agent that inhibits CYP17, antagonizes the
androgen receptor (AR), and reduces AR expression in prostate cancer cells by causing an …
被引用次数：78 相关文章
[PDF] archive.org

[PDF][PDF] Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer

B Montgomery, MA Eisenberger, MB Rettig, F Chu… - scholar.archive.org
Purpose: Galeterone is a selective, multitargeted agent that inhibits CYP17, antagonizes the
androgen receptor (AR), and reduces AR expression in prostate cancer cells by causing an …

Androgen Receptor Modulation Optimized for Response (ARMOR) phase i and II studies: Galeterone for the treatment of castration-resistant prostate cancer

B Montgomery, MA Eisenberger… - Clinical Cancer …, 2016 - researchworks.creighton.edu
Abstract alanine aminotransferase alkaline phosphatase androgen receptor aspartate
aminotransferase bilirubin galeterone mineralocorticoid prostate specific antigen 3-hydroxy …

Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer

B Montgomery, MA Eisenberger, MB Rettig… - Clinical Cancer …, 2016 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Purpose: Galeterone is a selective,
multitargeted agent that inhibits CYP17, antagonizes the androgen receptor (AR), and …
[PDF] researchgate.net

[PDF][PDF] Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer

B Montgomery, MA Eisenberger, MB Rettig… - Clin Cancer …, 2016 - researchgate.net
Purpose: Galeterone is a selective, multitargeted agent that inhibits CYP17, antagonizes the
androgen receptor (AR), and reduces AR expression in prostate cancer cells by causing an …

Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer

B Montgomery, MA Eisenberger… - … : an official journal …, 2016 - pubmed.ncbi.nlm.nih.gov
Purpose Galeterone is a selective, multitargeted agent that inhibits CYP17, antagonizes the
androgen receptor (AR), and reduces AR expression in prostate cancer cells by causing an …

Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer

B Montgomery, MA Eisenberger, MB Rettig, F Chu… - 2016 - scholarworks.iupui.edu
Purpose: Galeterone is a selective, multitargeted agent that inhibits CYP17, antagonizes the
androgen receptor (AR), and reduces AR expression in prostate cancer cells by causing an …

Androgen Receptor Modulation Optimized for Response (ARMOR) phase i and II studies: Galeterone for the treatment of castration-resistant prostate cancer

B Montgomery, MA Eisenberger… - Clinical Cancer …, 2016 - jhu.pure.elsevier.com
Purpose: Galeterone is a selective, multitargeted agent that inhibits CYP17, antagonizes the
androgen receptor (AR), and reduces AR expression in prostate cancer cells by causing an …
[PDF] core.ac.uk

[PDF][PDF] Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer

B Montgomery, MA Eisenberger, MB Rettig, F Chu… - core.ac.uk
Purpose: Galeterone is a selective, multitargeted agent that inhibits CYP17, antagonizes the
androgen receptor (AR), and reduces AR expression in prostate cancer cells by causing an …

Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer.

B Montgomery, MA Eisenberger, MB Rettig… - … Cancer Research: an …, 2015 - europepmc.org
Purpose Galeterone is a selective, multitargeted agent that inhibits CYP17, antagonizes the
androgen receptor (AR), and reduces AR expression in prostate cancer cells by causing an …